Skip to main content

Endolipid therapeutics

Endolipid therapeutics is established in early 2021 with the participation of dr. David Martinez Selva and Dr. Rafael Simó, who will act as scientific director (CSO) and medical advisor on behalf of the VHIR, together with two external partners, Genesis Discovery, SL, (Genesis) and Dr. Albert Palomer, who will support the constitution of the new company.

Endolipid Therapeutics will develop new treatments for fatty liver disease based on scientific findings on a new therapeutic target with anti-fat accumulation and anti-inflammatory effects. This new target will also allow the development of anti-cellulite cosmetic applications.

Non-alcoholic fatty liver disease is a condition that affects one in four people worldwide. Despite the high prevalence of this disease, which is often associated with obesity or type 2 diabetes, until now only lifestyle recommendations have been offered before the diagnosis, such as following a healthy diet and exercising physical There is no drug approved by any regulatory agency (US FDA or EMA in Europe) for its treatment.

To date, researchers have conducted in vitro and in vivo experiments with positive results that will continue in the coming years with studies in animal models and later in humans.

It is expected that within five years, this technology can reach the market for the treatment of non-alcoholic fatty liver disease.

The company was founded in 2021.

Founder on the part of the VHIR

Rafael Simó Canonge

Dr. Rafael Simó Canonge

Cap del grup de recerca en Diabetis i Metabolisme i cap del Servei d'Endocrinologia i Nutrició de Vall d'Hebron
David Martínez Selva

Dr. David Martínez Selva

Investigador principal del grup de recerca en Diabetis i Metabolisme